Advertisement
Drug Discovery
Subscribe to Drug Discovery

The Lead

Synthetic Lethality Offers New Approach to Kill Tumor Cells

October 31, 2014 1:51 pm | News | Comments

A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs. Read more...              

FDA Approves Generic Alzheimer's Drug

October 30, 2014 12:52 pm | News | Comments

TWi...

AstraZeneca's Diabetes Treatment Gets FDA Approval

October 30, 2014 12:00 pm | News | Comments

AstraZeneca...

ESMO: Cancer Immunotherapy on the Road

October 29, 2014 12:20 pm | by Neil Canavan | Articles | Comments

Since cancer immunotherapy was declared the...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Boehringer Ingelheim Present Data on COPD Drug

October 28, 2014 1:22 pm | News | Comments

Boehringer Ingelheim presented data from the ANHELTO 1&2 studies that evaluated the co-administration of Spiriva HandiHaler plus Striverdi Respimat Inhalation Spray inhaler in patients with COPD. Read more...

Shining Light on Heart Disease Severity, Location

October 28, 2014 1:14 pm | News | Comments

Officials at a life sciences startup based on a Purdue University innovation say their company could help cardiologists improve the diagnosis of heart disease. Read more...                       

Drug Combination Shows Promise As Powerful Breast Cancer Treatment

October 28, 2014 9:23 am | News | Comments

Doctors discovered a potent drug combination that shows promise as a powerful treatment for breast cancer. Read more...                        

Advertisement

Actinium Announces Collaboration Plan on New Program

October 27, 2014 1:23 pm | News | Comments

Actinium Pharmaceuticals and Albert Einstein College of Medicine of Yeshiva University started development of an antibody construct. Read more...                   

Heart Drug May Help Treat ALS, Mouse Study Shows

October 27, 2014 11:46 am | by Michael C. Purdy | News | Comments

Digoxin, a medication used in the treatment of heart failure, may be adaptable for the treatment of ALS, suggests new research at Washington University School of Medicine in St. Louis. Read more...          

Gene Link to Seizures in Children After MMR Vaccine

October 27, 2014 11:08 am | News | Comments

Scientists in Denmark said they had found genetic clues to explain why a small number of children have febrile seizures—brief convulsions—after receiving the measles, mumps and rubella (MMR) vaccine. Read more...

New Research Offers Hope in Treating Sleeping Sickness

October 27, 2014 9:21 am | by Joe O'Connell | News | Comments

A new research paper presents hundreds of starting points for treating sleep sickness, a deadly disease that affects thousands of people annually. Read more...                 

AstraZeneca's Cancer Drug Gets Positive CHMP Review

October 24, 2014 1:16 pm | News | Comments

AstraZeneca announced that the CHMP of the EMA has adopted a positive opinion recommending the marketing authorisation of Lynparza (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer. Read more...

Advertisement

Study Finds Best Way to Treat Neck Pain

October 24, 2014 10:03 am | News | Comments

A multicenter study of 169 men and women with a common form of neck pain suggests that both spinal steroid injections and conservative treatment with physical therapy and painkillers work equally well to relieve pain in the short term. Read more...  

New Technique Achieved With Profound Implications for Drug Development

October 24, 2014 9:29 am | News | Comments

A team from The Scripps Research Institute has established a new C-H activation technique that opens the door to creating a broader range of pure molecules of one-handedness or “chirality” by eliminating previous starting-material limitations. Read more...

Experimental Breast Cancer Drug Has Promise in Combination Therapy

October 23, 2014 1:40 pm | News | Comments

Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St. Jude Children's Research Hospital scientists.  Read more...

Real-Time Tracking System Developed to Watch Dangerous Bacteria

October 23, 2014 1:02 pm | News | Comments

Combining a PET scanner with a new chemical tracer that selectively tags specific types of bacteria, Johns Hopkins researchers working with mice report they have devised a way to detect and monitor in real time infections. Read more...    

New Anti-Cancer Drug Shows Few Side-Effects in Mice

October 23, 2014 10:15 am | News | Comments

A new drug, known as OTS964, can eradicate aggressive human lung cancers transplanted into mice, according to a new report. Read more...                     

Advertisement

NIH Begins Early Human Clinical Trial of New Ebola Vaccine

October 22, 2014 2:00 pm | News | Comments

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. Read more...                

UNC Researchers Found New Characters In Cancer Cells

October 22, 2014 1:47 pm | News | Comments

UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a previously unknown subpopulation of melanoma cancer cells in blood vessels of tumors. Read more...            

Taiho Receives FDA Fast Track for Cancer Treatment

October 22, 2014 1:14 pm | News | Comments

Taiho Oncology Inc. announced that the FDA granted Fast Track designation for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer (mCRC). Read more...

Oramed Gets Positive Data From Oral Insulin Trial

October 22, 2014 10:03 am | News | Comments

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, reported positive top-line clinical results from its Phase 2a clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. Read more...

Neurocrine Announces Phase 3 Study for Inhibitor

October 21, 2014 2:40 pm | News | Comments

Neurocrine Biosciences Inc. announced that it has initiated a Phase 3 clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854.  Read more...                    

Researchers Demonstrate Advances in Creating Blood Cancer Treatment

October 21, 2014 2:33 pm | News | Comments

Researchers at NYU Langone Medical Center and elsewhere said that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. Read more...    

Lilly's Diabetes Treatment Receives NDA

October 21, 2014 2:19 pm | News | Comments

FDA has accepted the filing of a NDA for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes (T2D). Read more...       

Once CD8 T Cells Take on One Virus, They'll Fight Others Too

October 21, 2014 2:02 pm | News | Comments

Scientists think of CD8 T cells as long-lived cells that become tuned to fight just one pathogen, but a study finds that once CD8 T cells fight one pathogen, they also join the body's "innate" immune system, ready to answer the calls of the cytokine signals that are set off by a wide variety of infections. Read more...

Supercomputers Link Proteins to Drug Side Effects

October 21, 2014 1:46 pm | News | Comments

Lawrence Livermore National Laboratory researchers have discovered a high-tech method of using supercomputers to identify proteins that cause medications to have certain adverse drug reactions (ADR) or side effects. Read more...         

RegeneRx Proceeds With Phase 3 Eye Drop Study

October 21, 2014 10:43 am | News | Comments

RegeneRx announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea. Read more...

Boehringer Ingelheim Initiates Phase 3 Cancer Study

October 21, 2014 10:34 am | News | Comments

Boehringer Ingelheim announced enrollment of the first patient in a new global Phase 3 study in patients with mCRC. Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed each year. Read more...

New Class of Drugs Shows Promise for Treating Chronic Diarrhea

October 21, 2014 10:23 am | News | Comments

A pilot study testing a new type of drug in patients with chronic diarrhea has shown promising effects on reducing their symptoms. Read more...                                    

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading